JP6097690B2 - 抗ｃｘｃｌ１３抗体およびそれを用いる方法 - Google Patents

抗ｃｘｃｌ１３抗体およびそれを用いる方法 Download PDF

Info

Publication number
JP6097690B2
JP6097690B2 JP2013527309A JP2013527309A JP6097690B2 JP 6097690 B2 JP6097690 B2 JP 6097690B2 JP 2013527309 A JP2013527309 A JP 2013527309A JP 2013527309 A JP2013527309 A JP 2013527309A JP 6097690 B2 JP6097690 B2 JP 6097690B2
Authority
JP
Japan
Prior art keywords
antibody
cxcl13
antigen
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013527309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539369A5 (https=
JP2013539369A (ja
Inventor
クリマチェワ，エカテリーナ
パリス，マーク
スミス，アーネスト・エス
Original Assignee
ヴァクシネックス， インコーポレイテッド
ヴァクシネックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァクシネックス， インコーポレイテッド, ヴァクシネックス， インコーポレイテッド filed Critical ヴァクシネックス， インコーポレイテッド
Publication of JP2013539369A publication Critical patent/JP2013539369A/ja
Publication of JP2013539369A5 publication Critical patent/JP2013539369A5/ja
Application granted granted Critical
Publication of JP6097690B2 publication Critical patent/JP6097690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013527309A 2010-09-02 2011-09-01 抗ｃｘｃｌ１３抗体およびそれを用いる方法 Active JP6097690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37967210P 2010-09-02 2010-09-02
US61/379,672 2010-09-02
US201161481645P 2011-05-02 2011-05-02
US61/481,645 2011-05-02
PCT/US2011/050177 WO2012031099A2 (en) 2010-09-02 2011-09-01 Anti-cxcl13 antibodies and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016218182A Division JP2017099379A (ja) 2010-09-02 2016-11-08 抗ｃｘｃｌ１３抗体およびそれを用いる方法

Publications (3)

Publication Number Publication Date
JP2013539369A JP2013539369A (ja) 2013-10-24
JP2013539369A5 JP2013539369A5 (https=) 2014-10-16
JP6097690B2 true JP6097690B2 (ja) 2017-03-15

Family

ID=45773520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013527309A Active JP6097690B2 (ja) 2010-09-02 2011-09-01 抗ｃｘｃｌ１３抗体およびそれを用いる方法
JP2016218182A Withdrawn JP2017099379A (ja) 2010-09-02 2016-11-08 抗ｃｘｃｌ１３抗体およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016218182A Withdrawn JP2017099379A (ja) 2010-09-02 2016-11-08 抗ｃｘｃｌ１３抗体およびそれを用いる方法

Country Status (13)

Country Link
US (3) US9963504B2 (https=)
EP (1) EP2611832B1 (https=)
JP (2) JP6097690B2 (https=)
KR (1) KR101862236B1 (https=)
CN (1) CN103347896B (https=)
AU (1) AU2011295902B2 (https=)
BR (1) BR112013005145B1 (https=)
CA (1) CA2810217C (https=)
DK (1) DK2611832T3 (https=)
MX (1) MX353476B (https=)
NZ (1) NZ608318A (https=)
SG (1) SG188285A1 (https=)
WO (1) WO2012031099A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
CN103608680A (zh) 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
NZ629828A (en) * 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
HK1212628A1 (zh) * 2012-06-27 2016-06-17 吉安特科技公司 用於抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
CA2893249A1 (en) * 2012-12-07 2014-06-12 Baxter International Inc. Anti-mif antibody cell migration assay
EP2951204B1 (en) * 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
BR112015021964A2 (pt) * 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
IL262232B2 (en) 2016-04-22 2024-06-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (ko) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
CN112469735B (zh) 2018-09-18 2022-11-08 天境生物科技(上海)有限公司 用于治疗自发性疾病和癌症的抗cxcl13抗体
JP7748728B2 (ja) * 2020-06-11 2025-10-03 インペリアル・カレッジ・イノベーションズ・リミテッド 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
CN115975946A (zh) * 2022-12-01 2023-04-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 表达趋化因子cxcl10、cxcl13、ccl19的免疫细胞及其制备方法与应用
CN121652269B (zh) * 2026-02-05 2026-04-17 北京中杉金桥生物技术有限公司 一种抗人cxcl13兔单克隆抗体、制备方法及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6692920B1 (en) 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
WO1996039522A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1998011226A2 (en) 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP1268554A2 (de) 2000-03-31 2003-01-02 IPF Pharmaceuticals GmbH Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1613657A2 (en) * 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
EP1570857A1 (en) 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
CN1842540B (zh) 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
WO2007124414A2 (en) * 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20080227704A1 (en) * 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2008121940A1 (en) * 2007-03-30 2008-10-09 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20110300167A1 (en) 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
EP2951204B1 (en) 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
BR112015021964A2 (pt) 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos

Also Published As

Publication number Publication date
EP2611832B1 (en) 2017-11-29
KR20130101046A (ko) 2013-09-12
WO2012031099A2 (en) 2012-03-08
US11981730B2 (en) 2024-05-14
WO2012031099A3 (en) 2012-06-07
CA2810217C (en) 2019-03-12
EP2611832A2 (en) 2013-07-10
MX2013002495A (es) 2013-06-05
CN103347896B (zh) 2017-06-13
NZ608318A (en) 2015-03-27
CN103347896A (zh) 2013-10-09
US20180244764A1 (en) 2018-08-30
MX353476B (es) 2018-01-15
BR112013005145A2 (pt) 2016-05-10
US20140147447A1 (en) 2014-05-29
SG188285A1 (en) 2013-04-30
JP2013539369A (ja) 2013-10-24
DK2611832T3 (en) 2018-02-26
CA2810217A1 (en) 2012-03-08
EP2611832A4 (en) 2014-03-05
US20150050287A9 (en) 2015-02-19
KR101862236B1 (ko) 2018-05-29
BR112013005145B1 (pt) 2022-02-15
US10829550B2 (en) 2020-11-10
WO2012031099A9 (en) 2012-08-30
JP2017099379A (ja) 2017-06-08
AU2011295902B2 (en) 2014-12-04
US20210087263A1 (en) 2021-03-25
US9963504B2 (en) 2018-05-08
AU2011295902A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
US11981730B2 (en) Anti-CXCL13 antibodies and methods of using the same
US12006364B2 (en) Anti-CD100 antibodies and methods for using the same
KR102594327B1 (ko) 인간-유래의 항-디펩티드 반복체(dpr) 항체
AU2018261947B2 (en) Human anti-semaphorin 4D antibody
CN107074937B (zh) 人源抗亨廷顿蛋白(htt)抗体及其用途
US20160002325A1 (en) Anti-cxcl13 antibodies and associated epitope sequences
US11542322B2 (en) Nano-theranostics for Parkinson's disease
RU2776443C2 (ru) Антитела человека против семафорина 4d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170220

R150 Certificate of patent or registration of utility model

Ref document number: 6097690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250